Healthcare Services

Global Glycomic Therapeutics Market Set for Strong Expansion Reaching $424.67 Billion by 2030 at 17.6% CAGR

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Glycomic Therapeutics Market At The End Of The 2026–2030 Forecast Period?

The glycomic therapeutics market has experienced significant expansion in recent years. This market is projected to expand from $189.51 billion in 2025 to $221.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.1%. Historically, this growth is a result of progress in glycobiology research, the advancement of enzyme therapies, approvals for rare disease drugs, increased academic research funding, and expansion in biologics manufacturing.

The glycomic therapeutics market size is anticipated to experience substantial expansion in the coming years, reaching $424.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.6%. This projected increase is driven by factors such as the adoption of precision medicine, advancements in glycan biomarker discovery, the broadening of orphan drug pipelines, innovations in synthetic biology, and enhanced pharmaceutical research investment. Key developments expected during this period include a greater emphasis on glycan-based drug creation, an increasing focus on immune modulation treatments, the expanded application of enzyme replacement therapies, intensified research into rare and metabolic conditions, and the evolution of synthetic glycan technologies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11894&type=smp

Which Market Drivers Are Supporting The Expansion Of The Glycomic Therapeutics Market?

The rising incidence of diabetes is projected to fuel the expansion of the glycomic therapeutics market. Diabetes is a long-term health condition characterized by the body’s impaired capacity to manage blood sugar (glucose) levels. Within diabetic individuals, changes in glycans have been noted, potentially leading to insulin resistance and other metabolic issues. Distinct glycan patterns are valuable as biomarkers for identifying diabetes, forecasting its advancement, and assessing treatment effectiveness. For instance, in March 2025, as reported by GOV.UK, a UK-based non-profit government organization, the prevalence of type 2 diabetes recorded by GPs among adults was 7.0% for those aged 17 and over in England at March 2024, marking an increase from 6.8% at March 2023. Consequently, the growing prevalence of diabetes is propelling the growth of the glycomic therapeutics market.

What Segment Types Make Up The Glycomic Therapeutics Market?

The glycomic therapeutics market covered in this report is segmented –

1) By Class: Isolated, Synthetic

2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures

3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action

4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher’s Disease, Mps-1 And IV, Cancer, Alzheimer’s Disease, Influenza Type A And B, Other Indications

Subsegments:

1) By Isolated: Natural Glycans, Glycan Derivatives, Glycoproteins

2) By Synthetic: Chemically Synthesized Glycans, Recombinant Glycans, Glycopeptides

Which Trends Are Shaping The Future Of The Glycomic Therapeutics Market?

Leading companies operating within the glycomic therapeutics market are concentrating on developing innovative solutions, such as glyco-immune checkpoint inhibitors, to address tumor immune evasion and improve treatment effectiveness. Glyco-immune checkpoint inhibitors function by blocking immunosuppressive sugar molecules found on cancer cells, thereby assisting the immune system in better identifying and combating tumors. For instance, in June 2023, Palleon Pharmaceuticals Inc., a US-based biopharmaceutical company, reported that the initial patient received dosage in the combination therapy part of the Phase 1/2 GLIMMER-01 clinical trial. This trial is assessing their primary glyco-immunology candidate E-602 alongside cemiplimab (Libtayo®) in individuals suffering from advanced cancers. The study examines E-602 both as a standalone therapy and when combined with cemiplimab to evaluate its safety, pharmacodynamics, and anti-tumor effects. E-602 itself is a pioneering glyco-immune checkpoint inhibitor, engineered to enzymatically break down immunosuppressive sialoglycans present on tumor and immune cells, with the goal of re-establishing antitumor immunity.

Who Are The Key Players Driving Competition In The Glycomic Therapeutics Market?

Major companies operating in the glycomic therapeutics market are F Hoffmann-La Roche Ltd., Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ludger Ltd, GlycoMar Limited

Read the full glycomic therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

How Is The Glycomic Therapeutics Market Distributed Across Key Geographic Regions?

North America was the largest region in the glycomic therapeutics in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Glycomic Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11894&type=smp

Browse Through More Reports Similar to the Global Glycomic Therapeutics Market 2026, By The Business Research Company

Glucagon Like Peptide 1 Global Market Report

https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report

Weight Loss Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/weight-loss-drugs-global-market-report

Peptide Based Metabolic Disorders Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795